Can Previous Chemotherapy Affect the Outcome of Nivolumab
Treatment in Non-small Cell Lung Cancer?

J 2022

Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?

SVATON, Martin, Monika BRATOVÁ, Leona KOUBKOVA, Ondrej FISCHER, Bohuslav MELICHAR et. al.

Basic information

Original name

Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?

Authors

SVATON, Martin (203 Czech Republic, guarantor), Monika BRATOVÁ (203 Czech Republic, belonging to the institution), Leona KOUBKOVA, Ondrej FISCHER (203 Czech Republic), Bohuslav MELICHAR (203 Czech Republic), Michal HRNCIARIK (203 Czech Republic), Daniel DOLEZAL (203 Czech Republic), Ondrej BILEK (203 Czech Republic), Jana KREJCI (203 Czech Republic), Marie DROSSLEROVA (203 Czech Republic), Zdenka DLOUHA (203 Czech Republic), Jiri BLAZEK (203 Czech Republic), Petra MAJKOVA (203 Czech Republic), Lucie BROŽOVÁ (203 Czech Republic, belonging to the institution) and Marek STASTNY (203 Czech Republic)

Edition

Anticancer Research, Athens, International Institute of Anticancer Research, 2022, 0250-7005

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Greece

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.000

RIV identification code

RIV/00216224:14110/22:00126148

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.21873/anticanres.15677

UT WoS

000778640800010

Keywords in English

NSCLC; lung cancer; nivolumab; chemotherapy; overall survival; pemetrexed; taxanes; vinorelbine

Abstract

V originále

Aim: This study compared the results of nivolumab treatment in patients with pulmonary adenocarcinomas based upon previous chemotherapeutic regimens. Patients and Methods: The data source for this retrospective study was the Czech VILP registry of patients with nivolumab-treated adenocarcinomas in second and higher lines of treatment. In relation to objective response rate, progression-free interval, and overall survival, three comparisons of patient were made: A: Those treated in first line with cisplatin and pemetrexed versus carboplatin with paclitaxel or vinorelbine; B: treatment with cisplatin and pemetrexed versus carboplatin with paclitaxel/vinorelbine and bevacizumab; and C: treatment in previous lines with pemetrexed (first-line cisplatin and pemetrexed plus those treated in second line with pemetrexed) versus treatment with taxane (first-line carboplatin and paclitaxel only plus those treated with second-line docetaxel). Results: We observed no differences in objective response rate or progression-free survival between patients treated with the stated chemotherapeutic regimens. We observed a trend towards better overall survival for patients treated with carboplatin plus taxanes or vinorelbine with/without bevacizumab. Conclusion: From our overall survival data, a chemotherapeutic regimen of carboplatin plus taxanes or vinorelbine with/without bevacizumab might be a better partner for immunotherapy than a cisplatin and pemetrexedbased one.

Citovat

SVATON, Martin, Monika BRATOVÁ, Leona KOUBKOVA, Ondrej FISCHER, Bohuslav MELICHAR, Michal HRNCIARIK, Daniel DOLEZAL, Ondrej BILEK, Jana KREJCI, Marie DROSSLEROVA, Zdenka DLOUHA, Jiri BLAZEK, Petra MAJKOVA, Lucie BROŽOVÁ and Marek STASTNY. Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer? Anticancer Research. Athens: International Institute of Anticancer Research, 2022, vol. 42, No 4, p. 1987-1995. ISSN 0250-7005. Available from: https://dx.doi.org/10.21873/anticanres.15677.

@article{1863072,
   author = {Svaton, Martin and Bratová, Monika and Koubkova, Leona and Fischer, Ondrej and Melichar, Bohuslav and Hrnciarik, Michal and Dolezal, Daniel and Bilek, Ondrej and Krejci, Jana and Drosslerova, Marie and Dlouha, Zdenka and Blazek, Jiri and Majkova, Petra and Brožová, Lucie and Stastny, Marek},
   article_location = {Athens},
   article_number = {4},
   doi = {http://dx.doi.org/10.21873/anticanres.15677},
   keywords = {NSCLC; lung cancer; nivolumab; chemotherapy; overall survival; pemetrexed; taxanes; vinorelbine},
   language = {eng},
   issn = {0250-7005},
   journal = {Anticancer Research},
   title = {Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?},
   url = {https://ar.iiarjournals.org/content/42/4/1987},
   volume = {42},
   year = {2022}
}

TY  - JOUR
ID  - 1863072
AU  - Svaton, Martin - Bratová, Monika - Koubkova, Leona - Fischer, Ondrej - Melichar, Bohuslav - Hrnciarik, Michal - Dolezal, Daniel - Bilek, Ondrej - Krejci, Jana - Drosslerova, Marie - Dlouha, Zdenka - Blazek, Jiri - Majkova, Petra - Brožová, Lucie - Stastny, Marek
PY  - 2022
TI  - Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?
JF  - Anticancer Research
VL  - 42
IS  - 4
SP  - 1987-1995
EP  - 1987-1995
PB  - International Institute of Anticancer Research
SN  - 02507005
KW  - NSCLC
KW  - lung cancer
KW  - nivolumab
KW  - chemotherapy
KW  - overall survival
KW  - pemetrexed
KW  - taxanes
KW  - vinorelbine
UR  - https://ar.iiarjournals.org/content/42/4/1987
N2  - Aim: This study compared the results of nivolumab treatment in patients with pulmonary adenocarcinomas based upon previous chemotherapeutic regimens. Patients and Methods: The data source for this retrospective study was the Czech VILP registry of patients with nivolumab-treated adenocarcinomas in second and higher lines of treatment. In relation to objective response rate, progression-free interval, and overall survival, three comparisons of patient were made: A: Those treated in first line with cisplatin and pemetrexed versus carboplatin with paclitaxel or vinorelbine; B: treatment with cisplatin and pemetrexed versus carboplatin with paclitaxel/vinorelbine and bevacizumab; and C: treatment in previous lines with pemetrexed (first-line cisplatin and pemetrexed plus those treated in second line with pemetrexed) versus treatment with taxane (first-line carboplatin and paclitaxel only plus those treated with second-line docetaxel). Results: We observed no differences in objective response rate or progression-free survival between patients treated with the stated chemotherapeutic regimens. We observed a trend towards better overall survival for patients treated with carboplatin plus taxanes or vinorelbine with/without bevacizumab. Conclusion: From our overall survival data, a chemotherapeutic regimen of carboplatin plus taxanes or vinorelbine with/without bevacizumab might be a better partner for immunotherapy than a cisplatin and pemetrexedbased one.
ER  -

SVATON, Martin, Monika BRATOVÁ, Leona KOUBKOVA, Ondrej FISCHER, Bohuslav MELICHAR, Michal HRNCIARIK, Daniel DOLEZAL, Ondrej BILEK, Jana KREJCI, Marie DROSSLEROVA, Zdenka DLOUHA, Jiri BLAZEK, Petra MAJKOVA, Lucie BROŽOVÁ and Marek STASTNY. Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer? \textit{Anticancer Research}. Athens: International Institute of Anticancer Research, 2022, vol.~42, No~4, p.~1987-1995. ISSN~0250-7005. Available from: https://dx.doi.org/10.21873/anticanres.15677.

Detailed Information on Publication Record